Core Viewpoint - The article highlights the journey and ambitions of Zhu Yi, the founder of Baili Tianheng, emphasizing the company's transition from a generic drug business to a leading innovator in the pharmaceutical industry, with a focus on developing innovative cancer therapies and aiming to become a multinational corporation (MNC) within five years [1][4][36]. Company Development - Zhu Yi has maintained a rigorous work schedule since 2014, focusing on the company's clinical projects and data analysis, which has contributed to Baili Tianheng's market value exceeding 100 billion RMB [1][4]. - The company transitioned from a generic drug business to innovative drug development, with significant milestones including a $8 billion licensing deal for its cancer drug BL-B01D1 with Bristol-Myers Squibb (BMS) [2][4]. - Baili Tianheng has become the third innovative drug company in A-shares to surpass a market value of 100 billion RMB, recently securing a nearly 4 billion RMB private placement [4][41]. Innovation and Research - The company has 14 innovative drugs in clinical stages, with BL-B01D1 being the only EGFR×HER3 bispecific ADC in Phase III trials globally, targeting various cancers [26][30]. - The focus on ADC (antibody-drug conjugates) is highlighted as a key strategy for attacking tumors effectively [31]. Business Strategy - Zhu Yi emphasizes a disciplined approach to business development (BD), advocating for high-value deals and maintaining a strong internal structure to support innovative projects [7][8]. - The company plans to expand its commercial team significantly, aiming for 2000-3000 personnel in the first year of commercialization for BL-B01D1, while reducing its generic drug sales team [28]. Financial Strategy - Baili Tianheng is actively seeking funding to support its ambitious plans, including a recent 4 billion RMB private placement and potential future funding from BMS [41]. - The company acknowledges the high costs associated with overseas clinical trials compared to domestic ones, necessitating additional funding [40]. Future Goals - Zhu Yi aims for Baili Tianheng to establish itself as a multinational corporation within five years, focusing on building capabilities in global clinical development and commercialization [5][36][37]. - The company is committed to maintaining a high level of operational efficiency and innovation, with a focus on leveraging advanced technologies and methodologies in drug development [33][34].
62岁“霸总”，每周做药100小时，坐拥千亿市值｜36氪专访
3 6 Ke·2025-08-28 02:36